You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameRitonavir
Accession NumberDB00503  (APRD00312)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionAn HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. [PubChem]
Structure
Thumb
Synonyms
Norvir
Ritonavir
Ritonavirum
External Identifiers
  • Abbott 84538
  • ABT 538
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
NorvirTablet, film coated100 mg/1OralREMEDYREPACK INC.2015-07-30Not applicableUs
NorvirSolution80 mgOralAbbvie Corporation1996-09-25Not applicableCanada
NorvirSolution80 mg/mLOralAbb Vie Inc.2010-05-06Not applicableUs
NorvirTablet, film coated100 mg/1OralA S Medication Solutions2010-05-06Not applicableUs
NorvirTablet100 mgOralAbbvie Corporation2010-12-17Not applicableCanada
NorvirTablet, film coated100 mg/1OralAbb Vie Inc.2010-05-06Not applicableUs
NorvirTablet, film coated100 mg/1OralA S Medication Solutions2010-05-06Not applicableUs
NorvirCapsule100 mgOralAbbvie Corporation1996-09-162012-11-08Canada
NorvirCapsule100 mg/1OralAbb Vie Inc.2010-05-06Not applicableUs
Norvir SecCapsule100 mgOralAbbvie Corporation2000-01-072014-11-25Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
BusvirConifarma
EmpetusEmcure
NormuneGrey Inversiones
Brand mixtures
NameLabellerIngredients
Holkira PakAbbvie Corporation
KaletraHHS/Program Support Center/Supply Service Center
TechnivieAbbvie Corporation
Viekira PakAbb Vie Inc.
Viekira XRAbb Vie Inc.
SaltsNot Available
Categories
UNIIO3J8G9O825
CAS number155213-67-5
WeightAverage: 720.944
Monoisotopic: 720.312760056
Chemical FormulaC37H48N6O5S2
InChI KeyNCDNCNXCDXHOMX-XGKFQTDJSA-N
InChI
InChI=1S/C37H48N6O5S2/c1-24(2)33(42-36(46)43(5)20-29-22-49-35(40-29)25(3)4)34(45)39-28(16-26-12-8-6-9-13-26)18-32(44)31(17-27-14-10-7-11-15-27)41-37(47)48-21-30-19-38-23-50-30/h6-15,19,22-25,28,31-33,44H,16-18,20-21H2,1-5H3,(H,39,45)(H,41,47)(H,42,46)/t28-,31-,32-,33-/m0/s1
IUPAC Name
1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[(2S)-3-methyl-2-{[methyl({[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl})carbamoyl]amino}butanamido]-1,6-diphenylhexan-2-yl]carbamate
SMILES
CC(C)[[email protected]](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[[email protected]](C[[email protected]](O)[[email protected]](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
Pharmacology
IndicationIndicated in combination with other antiretroviral agents for the treatment of HIV-infection.
Structured Indications
PharmacodynamicsRitonavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Protease inhibitors block the part of HIV called protease. HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Ritonavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs.
Mechanism of actionRitonavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.
TargetKindPharmacological actionActionsOrganismUniProt ID
Pol polyproteinProteinyes
inhibitor
Human immunodeficiency virus 1Q72874 details
Related Articles
AbsorptionThe absolute bioavailability of ritonavir has not been determined.
Volume of distributionNot Available
Protein binding98-99%
Metabolism

Hepatic. Five metabolites have been identified. The isopropylthiazole oxidation metabolite (M-2) is the major metabolite and has antiviral activity similar to that of ritonavir, however, plasma concentrations are low. The cytochrome P450 enzymes CYP3A and CYP2D6 are primarily involved in the metabolism of ritonavir.

SubstrateEnzymesProduct
Ritonavir
N-DesmethylritonavirDetails
Ritonavir
Hydroxy RitonavirDetails
Ritonavir
Ritonavir metabolite M1Details
Ritonavir
Ritonavir metabolite M11Details
Route of eliminationNot Available
Half life3-5 hours
ClearanceNot Available
ToxicityHuman experience of acute overdose with ritonavir is limited. One patient in clinical trials took ritonavir 1500 mg/day for two days. The patient reported paresthesias which resolved after the dose was decreased. A post-marketing case of renal failure with eosinophilia has been reported with ritonavir overdose. The approximate lethal dose was found to be greater than 20 times the related human dose in rats and 10 times the related human dose in mice.
Affected organisms
  • Human Immunodeficiency Virus
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Ritonavir.Investigational
19-norandrostenedioneThe serum concentration of 19-norandrostenedione can be increased when it is combined with Ritonavir.Experimental, Illicit
4-AndrostenedioneThe serum concentration of 4-Androstenedione can be increased when it is combined with Ritonavir.Experimental, Illicit
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Ritonavir.Experimental, Illicit
5-androstenedioneThe serum concentration of 5-androstenedione can be increased when it is combined with Ritonavir.Experimental, Illicit
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Ritonavir.Approved, Investigational
AbirateroneThe serum concentration of Ritonavir can be increased when it is combined with Abiraterone.Approved
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Ritonavir.Approved, Investigational
AcebutololThe serum concentration of Acebutolol can be decreased when it is combined with Ritonavir.Approved
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Ritonavir.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Ritonavir.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Ritonavir.Withdrawn
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Ritonavir.Approved
Acetylsalicylic acidThe metabolism of Acetylsalicylic acid can be decreased when combined with Ritonavir.Approved, Vet Approved
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Ritonavir.Approved
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Ritonavir.Approved
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Ritonavir.Experimental
AjmalineThe metabolism of Ajmaline can be decreased when combined with Ritonavir.Approved
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Ritonavir.Approved, Vet Approved
AlclometasoneThe metabolism of Alclometasone can be decreased when combined with Ritonavir.Approved
AldosteroneThe serum concentration of Aldosterone can be decreased when it is combined with Ritonavir.Experimental
AlectinibThe serum concentration of Ritonavir can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Alfentanil can be increased when it is combined with Ritonavir.Approved, Illicit
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Ritonavir.Approved, Investigational
AliskirenThe metabolism of Aliskiren can be decreased when combined with Ritonavir.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be decreased when it is combined with Ritonavir.Approved, Investigational
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Ritonavir.Approved
AlmotriptanThe serum concentration of Almotriptan can be increased when it is combined with Ritonavir.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Ritonavir.Approved
AlosetronThe serum concentration of Alosetron can be increased when it is combined with Ritonavir.Approved, Withdrawn
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Ritonavir.Approved, Illicit, Investigational
AlprenololThe metabolism of Alprenolol can be decreased when combined with Ritonavir.Approved, Withdrawn
AmantadineThe serum concentration of Ritonavir can be increased when it is combined with Amantadine.Approved
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Ritonavir.Approved, Investigational
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Ritonavir.Approved
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Ritonavir.Experimental
AmcinonideThe serum concentration of Amcinonide can be increased when it is combined with Ritonavir.Approved
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Ritonavir.Illicit, Withdrawn
Aminohippuric acidThe serum concentration of Ritonavir can be increased when it is combined with Aminohippuric acid.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Ritonavir.Approved, Withdrawn
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Ritonavir.Approved
AmiodaroneThe serum concentration of Amiodarone can be increased when it is combined with Ritonavir.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Ritonavir.Approved
AmlodipineThe metabolism of Amlodipine can be decreased when combined with Ritonavir.Approved
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Ritonavir.Approved
AmoxapineThe metabolism of Amoxapine can be decreased when combined with Ritonavir.Approved
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Ritonavir.Approved, Illicit
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Ritonavir.Approved
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Ritonavir.Approved
AnagrelideRitonavir may increase the QTc-prolonging activities of Anagrelide.Approved
AnecortaveThe serum concentration of Anecortave can be increased when it is combined with Ritonavir.Investigational
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Ritonavir.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Ritonavir.Approved
ApremilastThe metabolism of Apremilast can be decreased when combined with Ritonavir.Approved, Investigational
AprepitantThe serum concentration of Ritonavir can be increased when it is combined with Aprepitant.Approved, Investigational
AprindineThe metabolism of Aprindine can be decreased when combined with Ritonavir.Approved
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Ritonavir.Approved, Investigational
ArgatrobanThe metabolism of Argatroban can be decreased when combined with Ritonavir.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ritonavir.Approved, Investigational
Arsenic trioxideRitonavir may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherThe metabolism of Artemether can be decreased when combined with Ritonavir.Approved
AsenapineThe metabolism of Asenapine can be decreased when combined with Ritonavir.Approved
AstemizoleThe serum concentration of Astemizole can be increased when it is combined with Ritonavir.Approved, Withdrawn
AtazanavirThe serum concentration of Ritonavir can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Atenolol can be decreased when it is combined with Ritonavir.Approved
AtomoxetineThe serum concentration of Atomoxetine can be increased when it is combined with Ritonavir.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Ritonavir.Approved
AtovaquoneThe serum concentration of Atovaquone can be decreased when it is combined with Ritonavir.Approved
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Ritonavir.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Ritonavir.Approved, Investigational
AzelastineThe metabolism of Azelastine can be decreased when combined with Ritonavir.Approved
AzithromycinThe metabolism of Azithromycin can be decreased when combined with Ritonavir.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Ritonavir.Investigational
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Ritonavir.Investigational
BarnidipineThe serum concentration of Barnidipine can be increased when it is combined with Ritonavir.Approved
BeclomethasoneThe serum concentration of Beclomethasone can be increased when it is combined with Ritonavir.Investigational
Beclomethasone dipropionateThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Ritonavir.Approved, Investigational
BedaquilineThe serum concentration of Bedaquiline can be increased when it is combined with Ritonavir.Approved
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Ritonavir.Approved
BenzocaineThe serum concentration of Ritonavir can be increased when it is combined with Benzocaine.Approved
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Ritonavir.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Ritonavir.Approved
BepridilThe metabolism of Bepridil can be decreased when combined with Ritonavir.Approved, Withdrawn
BeraprostThe metabolism of Beraprost can be decreased when combined with Ritonavir.Investigational
BetamethasoneThe serum concentration of Betamethasone can be decreased when it is combined with Ritonavir.Approved, Vet Approved
BetaxololThe metabolism of Betaxolol can be decreased when combined with Ritonavir.Approved
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Ritonavir.Approved, Investigational
BezafibrateThe metabolism of Bezafibrate can be decreased when combined with Ritonavir.Approved
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Ritonavir.Approved
BiperidenThe serum concentration of Ritonavir can be increased when it is combined with Biperiden.Approved
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Ritonavir.Approved
BoceprevirThe serum concentration of Boceprevir can be decreased when it is combined with Ritonavir.Approved
BortezomibThe serum concentration of Bortezomib can be increased when it is combined with Ritonavir.Approved, Investigational
BosentanThe serum concentration of Bosentan can be increased when it is combined with Ritonavir.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Ritonavir.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Ritonavir.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Ritonavir.Approved
BrinzolamideThe serum concentration of Brinzolamide can be increased when it is combined with Ritonavir.Approved
BromazepamThe metabolism of Bromazepam can be decreased when combined with Ritonavir.Approved, Illicit
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Ritonavir.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Ritonavir.Approved
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Ritonavir.Approved
BudesonideThe metabolism of Budesonide can be decreased when combined with Ritonavir.Approved
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Ritonavir.Withdrawn
BufuralolThe metabolism of Bufuralol can be decreased when combined with Ritonavir.Experimental, Investigational
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Ritonavir.Approved, Investigational
BuprenorphineThe serum concentration of Buprenorphine can be increased when it is combined with Ritonavir.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of Bupropion can be decreased when it is combined with Ritonavir.Approved
BuspironeThe metabolism of Buspirone can be decreased when combined with Ritonavir.Approved, Investigational
BusulfanThe metabolism of Busulfan can be decreased when combined with Ritonavir.Approved, Investigational
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Ritonavir.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Ritonavir.Approved
CabozantinibThe serum concentration of Cabozantinib can be increased when it is combined with Ritonavir.Approved
CaffeineThe metabolism of Caffeine can be decreased when combined with Ritonavir.Approved
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Ritonavir.Approved, Nutraceutical
CamptothecinThe serum concentration of Camptothecin can be decreased when it is combined with Ritonavir.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be decreased when it is combined with Ritonavir.Approved
CandesartanThe serum concentration of Ritonavir can be increased when it is combined with Candesartan.Approved
CaptoprilThe metabolism of Captopril can be decreased when combined with Ritonavir.Approved
CarbamazepineThe metabolism of Ritonavir can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Ritonavir.Approved
CarfilzomibThe serum concentration of Carfilzomib can be decreased when it is combined with Ritonavir.Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Ritonavir.Approved
CarteololThe metabolism of Carteolol can be decreased when combined with Ritonavir.Approved
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Ritonavir.Approved, Investigational
CaspofunginThe serum concentration of Ritonavir can be increased when it is combined with Caspofungin.Approved
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Ritonavir.Experimental
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Ritonavir.Approved, Investigational
CeliprololThe metabolism of Celiprolol can be decreased when combined with Ritonavir.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Ritonavir.Approved, Vet Approved
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Ritonavir.Approved
CerivastatinThe metabolism of Cerivastatin can be decreased when combined with Ritonavir.Withdrawn
CevimelineThe metabolism of Cevimeline can be decreased when combined with Ritonavir.Approved
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Ritonavir.Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Ritonavir.Approved, Illicit
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Ritonavir.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Ritonavir.Withdrawn
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Ritonavir.Approved
ChlorpromazineThe metabolism of Chlorpromazine can be decreased when combined with Ritonavir.Approved, Vet Approved
ChlorpropamideThe serum concentration of Ritonavir can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Ritonavir can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Ritonavir.Approved
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Ritonavir.Approved, Nutraceutical
CholesterolThe serum concentration of Ritonavir can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Ritonavir can be decreased when it is combined with Cholic Acid.Approved
CiclesonideThe metabolism of Ciclesonide can be decreased when combined with Ritonavir.Approved, Investigational
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Ritonavir.Experimental
CilazaprilThe serum concentration of Ritonavir can be increased when it is combined with Cilazapril.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Ritonavir.Approved
CimetidineThe serum concentration of Cimetidine can be decreased when it is combined with Ritonavir.Approved
CinacalcetThe metabolism of Cinacalcet can be decreased when combined with Ritonavir.Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Ritonavir.Approved
CiprofloxacinRitonavir may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Ritonavir.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be decreased when it is combined with Ritonavir.Approved
CitalopramThe metabolism of Citalopram can be decreased when combined with Ritonavir.Approved
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Ritonavir.Approved
ClemastineThe metabolism of Ritonavir can be decreased when combined with Clemastine.Approved
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Ritonavir.Approved
ClindamycinThe metabolism of Clindamycin can be decreased when combined with Ritonavir.Approved, Vet Approved
ClobazamThe metabolism of Clobazam can be decreased when combined with Ritonavir.Approved, Illicit
ClobetasolThe serum concentration of Clobetasol can be increased when it is combined with Ritonavir.Investigational
Clobetasol propionateThe serum concentration of Clobetasol propionate can be increased when it is combined with Ritonavir.Approved
ClocortoloneThe serum concentration of Clocortolone can be increased when it is combined with Ritonavir.Approved
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Ritonavir.Approved, Investigational
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Ritonavir.Approved
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Ritonavir.Investigational
ClomifeneThe serum concentration of Clomifene can be decreased when it is combined with Ritonavir.Approved, Investigational
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Ritonavir.Approved, Vet Approved
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Ritonavir.Approved, Illicit
ClonidineThe metabolism of Clonidine can be decreased when combined with Ritonavir.Approved
ClopidogrelThe serum concentration of Ritonavir can be increased when it is combined with Clopidogrel.Approved, Nutraceutical
ClorazepateThe serum concentration of Clorazepate can be increased when it is combined with Ritonavir.Approved, Illicit
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Ritonavir.Approved, Illicit
ClotrimazoleThe metabolism of Ritonavir can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Clozapine can be decreased when combined with Ritonavir.Approved
CobicistatThe serum concentration of Ritonavir can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Ritonavir.Approved
CocaineThe metabolism of Cocaine can be decreased when combined with Ritonavir.Approved, Illicit
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Ritonavir.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Ritonavir.Approved
ColforsinThe serum concentration of Ritonavir can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Ritonavir.Approved, Investigational
Conjugated Equine EstrogensThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Ritonavir.Approved
Cortisone acetateThe metabolism of Cortisone acetate can be decreased when combined with Ritonavir.Approved
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Ritonavir.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Ritonavir.Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Ritonavir is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Ritonavir.Approved, Investigational, Vet Approved
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Ritonavir.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Ritonavir can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
CytarabineThe metabolism of Cytarabine can be decreased when combined with Ritonavir.Approved, Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Ritonavir.Approved
DabrafenibThe serum concentration of Ritonavir can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Daclatasvir can be increased when it is combined with Ritonavir.Approved
DactinomycinThe serum concentration of Dactinomycin can be decreased when it is combined with Ritonavir.Approved
DantroleneThe metabolism of Dantrolene can be decreased when combined with Ritonavir.Approved
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Ritonavir.Approved
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Ritonavir.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Ritonavir.Approved, Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Ritonavir.Approved, Investigational
DarunavirThe serum concentration of Darunavir can be decreased when it is combined with Ritonavir.Approved
DasabuvirThe serum concentration of Dasabuvir can be increased when it is combined with Ritonavir.Approved
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Ritonavir.Approved, Investigational
DaunorubicinThe metabolism of Daunorubicin can be decreased when combined with Ritonavir.Approved
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Ritonavir.Approved
DeferasiroxThe serum concentration of Deferasirox can be decreased when it is combined with Ritonavir.Approved, Investigational
dehydroepiandrosterone sulfateThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Ritonavir.Investigational
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Ritonavir.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Ritonavir.Investigational
DesipramineThe metabolism of Desipramine can be decreased when combined with Ritonavir.Approved
DesloratadineThe serum concentration of Ritonavir can be increased when it is combined with Desloratadine.Approved, Investigational
DesoximetasoneThe serum concentration of Desoximetasone can be increased when it is combined with Ritonavir.Approved
Desoxycorticosterone acetateThe serum concentration of Desoxycorticosterone acetate can be increased when it is combined with Ritonavir.Approved
Desoxycorticosterone PivalateThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Ritonavir.Experimental, Vet Approved
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Ritonavir.Approved
DexamethasoneThe metabolism of Dexamethasone can be decreased when combined with Ritonavir.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe serum concentration of Dexamethasone isonicotinate can be increased when it is combined with Ritonavir.Vet Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Ritonavir.Approved, Illicit, Withdrawn
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Ritonavir.Approved
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Ritonavir.Approved, Illicit
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Ritonavir.Approved
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Ritonavir.Approved, Illicit, Withdrawn
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Ritonavir.Approved, Illicit, Vet Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Ritonavir.Approved, Vet Approved
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Ritonavir.Approved
DienogestThe serum concentration of Dienogest can be increased when it is combined with Ritonavir.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Ritonavir.Approved
DiflorasoneThe serum concentration of Diflorasone can be increased when it is combined with Ritonavir.Approved
DifluocortoloneThe serum concentration of Difluocortolone can be increased when it is combined with Ritonavir.Approved
DifluprednateThe serum concentration of Difluprednate can be increased when it is combined with Ritonavir.Approved
DigitoxinThe metabolism of Digitoxin can be decreased when combined with Ritonavir.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Ritonavir.Approved
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Ritonavir.Approved, Illicit
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Ritonavir.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be decreased when it is combined with Ritonavir.Illicit
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Ritonavir.Approved
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Ritonavir.Approved
DipyridamoleThe serum concentration of Dipyridamole can be decreased when it is combined with Ritonavir.Approved
DisopyramideThe metabolism of Disopyramide can be decreased when combined with Ritonavir.Approved
DisulfiramThe risk or severity of adverse effects can be increased when Ritonavir is combined with Disulfiram.Approved
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Ritonavir.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Ritonavir.Approved
DolasetronThe metabolism of Dolasetron can be decreased when combined with Ritonavir.Approved
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Ritonavir.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Ritonavir.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Ritonavir.Approved
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Ritonavir.Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Ritonavir.Approved
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Ritonavir.Approved
DoxepinThe metabolism of Doxepin can be decreased when combined with Ritonavir.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Ritonavir.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Ritonavir.Approved, Investigational
DoxycyclineThe metabolism of Ritonavir can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Ritonavir.Approved, Illicit
DronedaroneThe serum concentration of Dronedarone can be increased when it is combined with Ritonavir.Approved
DroperidolRitonavir may increase the QTc-prolonging activities of Droperidol.Approved, Vet Approved
DrospirenoneThe serum concentration of Drospirenone can be increased when it is combined with Ritonavir.Approved
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Ritonavir.Approved
DuloxetineThe serum concentration of Duloxetine can be increased when it is combined with Ritonavir.Approved
DutasterideThe serum concentration of Dutasteride can be increased when it is combined with Ritonavir.Approved, Investigational
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Ritonavir.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Ritonavir.Approved
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Ritonavir.Approved, Investigational
ElbasvirThe serum concentration of Ritonavir can be increased when it is combined with Elbasvir.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Ritonavir.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Ritonavir.Approved
EltrombopagThe metabolism of Eltrombopag can be decreased when combined with Ritonavir.Approved
EluxadolineThe serum concentration of Eluxadoline can be increased when it is combined with Ritonavir.Approved
ElvitegravirThe metabolism of Elvitegravir can be decreased when combined with Ritonavir.Approved
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Ritonavir.Approved
EnalaprilThe metabolism of Enalapril can be decreased when combined with Ritonavir.Approved, Vet Approved
EncainideThe metabolism of Encainide can be decreased when combined with Ritonavir.Approved, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Ritonavir.Investigational
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Ritonavir.Approved, Investigational
EnzalutamideThe serum concentration of Enzalutamide can be increased when it is combined with Ritonavir.Approved
EpinastineThe metabolism of Epinastine can be decreased when combined with Ritonavir.Approved, Investigational
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Ritonavir.Approved
EquileninThe serum concentration of Equilenin can be increased when it is combined with Ritonavir.Experimental
EquilinThe serum concentration of Equilin can be increased when it is combined with Ritonavir.Approved
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Ritonavir.Approved, Nutraceutical
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Ritonavir.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Ritonavir.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Ritonavir.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Ritonavir.Approved, Investigational
ErythromycinThe metabolism of Erythromycin can be decreased when combined with Ritonavir.Approved, Vet Approved
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Ritonavir.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Ritonavir can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Ritonavir.Investigational
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Ritonavir.Approved, Investigational
EstazolamThe serum concentration of Estazolam can be increased when it is combined with Ritonavir.Approved, Illicit
EstradiolThe metabolism of Estradiol can be decreased when combined with Ritonavir.Approved, Investigational, Vet Approved
Estradiol valerate/DienogestThe metabolism of Estradiol valerate/Dienogest can be decreased when combined with Ritonavir.Approved
EstramustineThe metabolism of Estramustine can be decreased when combined with Ritonavir.Approved
EstriolThe serum concentration of Estriol can be decreased when it is combined with Ritonavir.Approved, Vet Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Ritonavir.Approved
EstroneThe metabolism of Estrone can be decreased when combined with Ritonavir.Approved
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Ritonavir.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Ritonavir.Approved
EthanolThe metabolism of Ethanol can be decreased when combined with Ritonavir.Approved
Ethinyl EstradiolThe metabolism of Ethinyl Estradiol can be decreased when combined with Ritonavir.Approved
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Ritonavir.Approved
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Ritonavir.Approved, Illicit
EtizolamThe serum concentration of Etizolam can be increased when it is combined with Ritonavir.Approved
EtonogestrelThe metabolism of Etonogestrel can be decreased when combined with Ritonavir.Approved, Investigational
EtoposideThe metabolism of Etoposide can be decreased when combined with Ritonavir.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Ritonavir.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Ritonavir.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Ritonavir.Approved
ExemestaneThe metabolism of Exemestane can be decreased when combined with Ritonavir.Approved, Investigational
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Ritonavir.Approved, Investigational
EzetimibeThe serum concentration of Ezetimibe can be decreased when it is combined with Ritonavir.Approved
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Ritonavir.Approved
FelbamateThe metabolism of Felbamate can be decreased when combined with Ritonavir.Approved
FelodipineThe metabolism of Felodipine can be decreased when combined with Ritonavir.Approved, Investigational
FenofibrateThe metabolism of Fenofibrate can be decreased when combined with Ritonavir.Approved
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Ritonavir.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Ritonavir.Approved
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Ritonavir.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be decreased when it is combined with Ritonavir.Approved
FinasterideThe metabolism of Finasteride can be decreased when combined with Ritonavir.Approved
FingolimodThe metabolism of Fingolimod can be decreased when combined with Ritonavir.Approved, Investigational
FlecainideThe serum concentration of Flecainide can be increased when it is combined with Ritonavir.Approved, Withdrawn
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Ritonavir.Approved
fluasteroneThe serum concentration of fluasterone can be increased when it is combined with Ritonavir.Investigational
FluconazoleThe metabolism of Ritonavir can be decreased when combined with Fluconazole.Approved
FludrocortisoneThe serum concentration of Fludrocortisone can be increased when it is combined with Ritonavir.Approved
FlumethasoneThe serum concentration of Flumethasone can be increased when it is combined with Ritonavir.Approved, Vet Approved
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Ritonavir.Approved
FlunisolideThe metabolism of Flunisolide can be decreased when combined with Ritonavir.Approved, Investigational
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Ritonavir.Approved, Illicit
Fluocinolone AcetonideThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Ritonavir.Approved, Investigational, Vet Approved
FluocinonideThe serum concentration of Fluocinonide can be increased when it is combined with Ritonavir.Approved, Investigational
FluocortoloneThe serum concentration of Fluocortolone can be increased when it is combined with Ritonavir.Approved, Withdrawn
FluorometholoneThe metabolism of Fluorometholone can be decreased when combined with Ritonavir.Approved
FluorouracilThe metabolism of Fluorouracil can be decreased when combined with Ritonavir.Approved
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Ritonavir.Approved, Vet Approved
FlupentixolRitonavir may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Ritonavir.Approved
FluprednideneThe serum concentration of Fluprednidene can be increased when it is combined with Ritonavir.Approved, Withdrawn
FluprednisoloneThe serum concentration of Fluprednisolone can be increased when it is combined with Ritonavir.Approved
FlurandrenolideThe serum concentration of Flurandrenolide can be increased when it is combined with Ritonavir.Approved
FlurazepamThe serum concentration of Flurazepam can be increased when it is combined with Ritonavir.Approved, Illicit
FlutamideThe metabolism of Flutamide can be decreased when combined with Ritonavir.Approved
Fluticasone furoateThe metabolism of Fluticasone furoate can be decreased when combined with Ritonavir.Approved
Fluticasone PropionateThe serum concentration of Fluticasone Propionate can be increased when it is combined with Ritonavir.Approved
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Ritonavir.Approved
FluvoxamineThe metabolism of Ritonavir can be decreased when combined with Fluvoxamine.Approved, Investigational
FormestaneThe serum concentration of Formestane can be increased when it is combined with Ritonavir.Approved, Investigational, Withdrawn
FormoterolThe metabolism of Formoterol can be decreased when combined with Ritonavir.Approved, Investigational
FosamprenavirThe metabolism of Fosamprenavir can be decreased when combined with Ritonavir.Approved
FosaprepitantThe serum concentration of Ritonavir can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Ritonavir can be decreased when it is combined with Fosphenytoin.Approved
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Ritonavir.Approved, Investigational
Fusidic AcidThe serum concentration of Fusidic Acid can be increased when it is combined with Ritonavir.Approved
Gadobenic acidRitonavir may increase the QTc-prolonging activities of Gadobenic acid.Approved
GalantamineThe metabolism of Galantamine can be decreased when combined with Ritonavir.Approved
GarlicThe serum concentration of Ritonavir can be decreased when it is combined with Garlic.Approved
GefitinibThe metabolism of Gefitinib can be decreased when combined with Ritonavir.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be decreased when it is combined with Ritonavir.Approved
GemfibrozilThe serum concentration of Ritonavir can be increased when it is combined with Gemfibrozil.Approved
GemifloxacinRitonavir may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Ritonavir can be increased when it is combined with Genistein.Investigational
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Ritonavir.Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Ritonavir.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Ritonavir.Approved
GlipizideThe metabolism of Glipizide can be decreased when combined with Ritonavir.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Ritonavir.Approved
GlyburideThe metabolism of Glyburide can be decreased when combined with Ritonavir.Approved
GlycerolThe serum concentration of Ritonavir can be increased when it is combined with Glycerol.Experimental
GoserelinRitonavir may increase the QTc-prolonging activities of Goserelin.Approved
Gramicidin DThe serum concentration of Ritonavir can be increased when it is combined with Gramicidin D.Approved
GranisetronThe metabolism of Granisetron can be decreased when combined with Ritonavir.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be decreased when it is combined with Ritonavir.Approved
GrepafloxacinThe metabolism of Grepafloxacin can be decreased when combined with Ritonavir.Withdrawn
GuanfacineThe serum concentration of Guanfacine can be increased when it is combined with Ritonavir.Approved, Investigational
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Ritonavir.Investigational
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Ritonavir.Approved
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Ritonavir.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Ritonavir.Approved, Vet Approved
HE3286The serum concentration of HE3286 can be increased when it is combined with Ritonavir.Investigational
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Ritonavir.Withdrawn
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Ritonavir.Approved
Histamine PhosphateThe metabolism of Histamine Phosphate can be decreased when combined with Ritonavir.Approved
HydrocodoneThe serum concentration of Hydrocodone can be decreased when it is combined with Ritonavir.Approved, Illicit
HydrocortisoneThe metabolism of Hydrocortisone can be decreased when combined with Ritonavir.Approved, Vet Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Ritonavir.Approved, Illicit
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Ritonavir.Approved
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Ritonavir.Approved
IbuprofenThe metabolism of Ibuprofen can be decreased when combined with Ritonavir.Approved
IbutilideRitonavir may increase the QTc-prolonging activities of Ibutilide.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Ritonavir.Approved
IdelalisibThe serum concentration of Ritonavir can be increased when it is combined with Idelalisib.Approved
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Ritonavir resulting in a loss in efficacy.Approved
IloperidoneThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Ritonavir.Approved
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Ritonavir.Approved
ImidafenacinThe serum concentration of Imidafenacin can be increased when it is combined with Ritonavir.Approved
ImipramineThe metabolism of Imipramine can be decreased when combined with Ritonavir.Approved
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Ritonavir.Approved, Investigational
IndacaterolThe metabolism of Indacaterol can be decreased when combined with Ritonavir.Approved
IndapamideThe metabolism of Indapamide can be decreased when combined with Ritonavir.Approved
IndinavirThe metabolism of Ritonavir can be decreased when combined with Indinavir.Approved
IndomethacinThe serum concentration of Indomethacin can be decreased when it is combined with Ritonavir.Approved, Investigational
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Ritonavir.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Ritonavir.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Ritonavir.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Ritonavir.Approved
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Ritonavir.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Ritonavir.Approved
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Ritonavir.Approved
IrbesartanThe metabolism of Irbesartan can be decreased when combined with Ritonavir.Approved, Investigational
IrinotecanThe serum concentration of the active metabolites of Irinotecan can be increased when Irinotecan is used in combination with Ritonavir.Approved, Investigational
IsavuconazoniumThe serum concentration of the active metabolites of Isavuconazonium can be increased when Isavuconazonium is used in combination with Ritonavir.Approved, Investigational
IsoniazidThe metabolism of Ritonavir can be decreased when combined with Isoniazid.Approved
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be decreased when combined with Ritonavir.Approved
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be decreased when combined with Ritonavir.Approved
IsradipineThe metabolism of Isradipine can be decreased when combined with Ritonavir.Approved
IstaroximeThe serum concentration of Istaroxime can be increased when it is combined with Ritonavir.Investigational
ItraconazoleThe serum concentration of Itraconazole can be increased when it is combined with Ritonavir.Approved, Investigational
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Ritonavir.Approved
IvacaftorThe serum concentration of Ivacaftor can be increased when it is combined with Ritonavir.Approved
IvermectinThe metabolism of Ivermectin can be decreased when combined with Ritonavir.Approved, Vet Approved
IxabepiloneThe serum concentration of Ixabepilone can be increased when it is combined with Ritonavir.Approved, Investigational
IxazomibThe metabolism of Ixazomib can be decreased when combined with Ritonavir.Approved
KetamineThe metabolism of Ketamine can be decreased when combined with Ritonavir.Approved, Vet Approved
KetazolamThe metabolism of Ketazolam can be decreased when combined with Ritonavir.Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Ritonavir.Approved
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Ritonavir.Approved, Investigational
KetoconazoleThe metabolism of Ketoconazole can be decreased when combined with Ritonavir.Approved, Investigational
LabetalolThe metabolism of Labetalol can be decreased when combined with Ritonavir.Approved
LacosamideThe serum concentration of Lacosamide can be increased when it is combined with Ritonavir.Approved
LamivudineThe serum concentration of Lamivudine can be decreased when it is combined with Ritonavir.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Ritonavir.Approved, Investigational
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Ritonavir.Approved, Investigational
LapatinibThe serum concentration of Lapatinib can be increased when it is combined with Ritonavir.Approved, Investigational
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Ritonavir.Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Ritonavir.Approved
LenalidomideThe serum concentration of Lenalidomide can be decreased when it is combined with Ritonavir.Approved
LenvatinibThe metabolism of Lenvatinib can be decreased when combined with Ritonavir.Approved
LercanidipineThe serum concentration of Lercanidipine can be increased when it is combined with Ritonavir.Approved, Investigational
LetrozoleThe metabolism of Letrozole can be decreased when combined with Ritonavir.Approved, Investigational
LeuprolideRitonavir may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be decreased when it is combined with Ritonavir.Approved, Investigational
LevobupivacaineThe serum concentration of Levobupivacaine can be increased when it is combined with Ritonavir.Approved
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Ritonavir.Approved
LevodopaThe metabolism of Levodopa can be decreased when combined with Ritonavir.Approved
LevofloxacinRitonavir may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Ritonavir.Approved
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Ritonavir.Approved
LevonorgestrelThe metabolism of Levonorgestrel can be decreased when combined with Ritonavir.Approved, Investigational
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Ritonavir.Approved
LicofeloneThe metabolism of Licofelone can be decreased when combined with Ritonavir.Investigational
LidocaineThe metabolism of Lidocaine can be decreased when combined with Ritonavir.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Ritonavir.Approved
LiothyronineThe serum concentration of Ritonavir can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Ritonavir can be decreased when it is combined with Liotrix.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Ritonavir.Approved
LisinoprilThe serum concentration of Ritonavir can be increased when it is combined with Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Ritonavir.Approved
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Ritonavir.Approved
LomustineThe metabolism of Lomustine can be decreased when combined with Ritonavir.Approved
LoperamideThe metabolism of Loperamide can be decreased when combined with Ritonavir.Approved
LopinavirThe serum concentration of Ritonavir can be increased when it is combined with Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Ritonavir.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Ritonavir.Approved
LosartanThe metabolism of Losartan can be decreased when combined with Ritonavir.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Ritonavir.Approved, Investigational
LuliconazoleThe serum concentration of Ritonavir can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Ritonavir can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe serum concentration of Lumefantrine can be increased when it is combined with Ritonavir.Approved
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Ritonavir.Approved
MacitentanThe serum concentration of Macitentan can be increased when it is combined with Ritonavir.Approved
MannitolThe serum concentration of Mannitol can be decreased when it is combined with Ritonavir.Approved, Investigational
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Ritonavir.Approved
MaravirocThe serum concentration of Maraviroc can be increased when it is combined with Ritonavir.Approved, Investigational
ME-609The serum concentration of ME-609 can be increased when it is combined with Ritonavir.Investigational
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Ritonavir.Approved, Vet Approved
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Ritonavir.Approved, Investigational
MedrysoneThe serum concentration of Medrysone can be increased when it is combined with Ritonavir.Approved
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Ritonavir.Approved
MefloquineThe metabolism of Mefloquine can be decreased when combined with Ritonavir.Approved
Megestrol acetateThe serum concentration of Ritonavir can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MelengestrolThe serum concentration of Melengestrol can be increased when it is combined with Ritonavir.Vet Approved
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Ritonavir.Approved, Vet Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Ritonavir.Investigational, Withdrawn
MeprobamateThe serum concentration of Ritonavir can be increased when it is combined with Meprobamate.Approved, Illicit
MequitazineThe serum concentration of Mequitazine can be increased when it is combined with Ritonavir.Approved
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Ritonavir.Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Ritonavir.Approved
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Ritonavir.Approved
MethadoneThe serum concentration of Methadone can be decreased when it is combined with Ritonavir.Approved
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Ritonavir.Experimental
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Ritonavir.Approved, Illicit
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Ritonavir.Illicit, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be decreased when it is combined with Ritonavir.Approved
MethotrimeprazineThe metabolism of Methotrimeprazine can be decreased when combined with Ritonavir.Approved
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Ritonavir.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Ritonavir.Approved, Vet Approved
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Ritonavir.Approved, Investigational
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Ritonavir.Approved, Vet Approved
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Ritonavir.Approved
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Ritonavir.Approved, Illicit, Withdrawn
MetoclopramideThe metabolism of Metoclopramide can be decreased when combined with Ritonavir.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Ritonavir.Approved, Investigational
MetronidazoleThe risk or severity of adverse effects can be increased when Ritonavir is combined with Metronidazole.Approved
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Ritonavir.Approved
MexiletineThe metabolism of Mexiletine can be decreased when combined with Ritonavir.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Ritonavir.Approved
MibefradilThe metabolism of Mibefradil can be decreased when combined with Ritonavir.Withdrawn
MiconazoleThe metabolism of Miconazole can be decreased when combined with Ritonavir.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Ritonavir.Approved, Illicit
MifepristoneMifepristone may increase the QTc-prolonging activities of Ritonavir.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Ritonavir.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Ritonavir.Approved
MinaprineThe metabolism of Minaprine can be decreased when combined with Ritonavir.Approved
MirabegronThe metabolism of Mirabegron can be decreased when combined with Ritonavir.Approved
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Ritonavir.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Ritonavir.Approved, Investigational
MitomycinThe serum concentration of Ritonavir can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Ritonavir can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be decreased when it is combined with Ritonavir.Approved, Investigational
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Ritonavir.Approved
ModafinilThe metabolism of Modafinil can be decreased when combined with Ritonavir.Approved, Investigational
MometasoneThe serum concentration of Mometasone can be increased when it is combined with Ritonavir.Approved, Vet Approved
MontelukastThe metabolism of Montelukast can be decreased when combined with Ritonavir.Approved
MorphineThe metabolism of Morphine can be decreased when combined with Ritonavir.Approved, Investigational
MoxifloxacinRitonavir may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
muraglitazarThe metabolism of muraglitazar can be decreased when combined with Ritonavir.Investigational
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Ritonavir.Approved, Investigational
NadololThe serum concentration of Nadolol can be decreased when it is combined with Ritonavir.Approved
NafcillinThe serum concentration of Ritonavir can be decreased when it is combined with Nafcillin.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Ritonavir.Approved
NaloxoneThe metabolism of Naloxone can be decreased when combined with Ritonavir.Approved, Vet Approved
NaltrexoneThe serum concentration of Ritonavir can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaproxenThe metabolism of Naproxen can be decreased when combined with Ritonavir.Approved, Vet Approved
NaringeninThe serum concentration of Ritonavir can be increased when it is combined with Naringenin.Experimental
NateglinideThe metabolism of Nateglinide can be decreased when combined with Ritonavir.Approved, Investigational
NCX 1022The serum concentration of NCX 1022 can be increased when it is combined with Ritonavir.Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Ritonavir.Approved, Investigational
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Ritonavir.Approved, Withdrawn
NelfinavirThe metabolism of Ritonavir can be decreased when combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Ritonavir can be increased when it is combined with Neostigmine.Approved, Vet Approved
NetupitantThe serum concentration of Ritonavir can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Ritonavir can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Nicardipine can be decreased when combined with Ritonavir.Approved
NicergolineThe metabolism of Nicergoline can be decreased when combined with Ritonavir.Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Ritonavir.Approved
NifedipineThe metabolism of Nifedipine can be decreased when combined with Ritonavir.Approved
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Ritonavir.Approved, Investigational
NilvadipineThe metabolism of Nilvadipine can be decreased when combined with Ritonavir.Approved
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Ritonavir.Approved
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Ritonavir.Approved
NisoldipineThe serum concentration of Nisoldipine can be increased when it is combined with Ritonavir.Approved
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Ritonavir.Approved
NitrendipineThe metabolism of Nitrendipine can be decreased when combined with Ritonavir.Approved
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Ritonavir.Approved, Vet Approved
NizatidineThe serum concentration of Nizatidine can be decreased when it is combined with Ritonavir.Approved
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Ritonavir.Approved
NorgestrelThe metabolism of Norgestrel can be decreased when combined with Ritonavir.Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Ritonavir.Approved
OfloxacinRitonavir may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineThe serum concentration of Olanzapine can be decreased when it is combined with Ritonavir.Approved, Investigational
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Ritonavir.Approved
Oleoyl estroneThe serum concentration of Oleoyl estrone can be increased when it is combined with Ritonavir.Investigational
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Ritonavir.Approved
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Ritonavir.Approved
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Ritonavir.Approved
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Ritonavir.Approved, Investigational, Vet Approved
OndansetronThe metabolism of Ondansetron can be decreased when combined with Ritonavir.Approved
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Ritonavir.Investigational
OrphenadrineThe metabolism of Orphenadrine can be decreased when combined with Ritonavir.Approved
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Ritonavir.Approved
OspemifeneThe serum concentration of Ospemifene can be increased when it is combined with Ritonavir.Approved
OxazepamThe metabolism of Oxazepam can be decreased when combined with Ritonavir.Approved
OxybutyninThe serum concentration of Oxybutynin can be increased when it is combined with Ritonavir.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Ritonavir is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Ritonavir.Approved, Investigational, Vet Approved
P-NitrophenolThe serum concentration of Ritonavir can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Ritonavir.Approved, Vet Approved
PalbociclibThe serum concentration of Palbociclib can be increased when it is combined with Ritonavir.Approved
PaliperidoneRitonavir may increase the QTc-prolonging activities of Paliperidone.Approved
Palmitic AcidThe serum concentration of Ritonavir can be increased when it is combined with Palmitic Acid.Experimental
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Ritonavir.Approved, Investigational
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Ritonavir.Approved, Investigational
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Ritonavir.Approved
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Ritonavir.Approved
ParamethasoneThe metabolism of Paramethasone can be decreased when combined with Ritonavir.Approved
ParecoxibThe serum concentration of Parecoxib can be increased when it is combined with Ritonavir.Approved
ParicalcitolThe serum concentration of Paricalcitol can be increased when it is combined with Ritonavir.Approved, Investigational
ParitaprevirThe serum concentration of Paritaprevir can be increased when it is combined with Ritonavir.Approved
ParoxetineThe metabolism of Paroxetine can be decreased when combined with Ritonavir.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Ritonavir.Approved
Peginterferon alfa-2bThe serum concentration of Ritonavir can be decreased when it is combined with Peginterferon alfa-2b.Approved
PentamidineThe metabolism of Pentamidine can be decreased when combined with Ritonavir.Approved
PentobarbitalThe metabolism of Ritonavir can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelThe metabolism of Perampanel can be decreased when combined with Ritonavir.Approved
PerflutrenRitonavir may increase the QTc-prolonging activities of Perflutren.Approved
PergolideThe metabolism of Pergolide can be decreased when combined with Ritonavir.Approved, Vet Approved, Withdrawn
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Ritonavir.Approved
PerindoprilThe serum concentration of Ritonavir can be increased when it is combined with Perindopril.Approved
PermethrinThe metabolism of Permethrin can be decreased when combined with Ritonavir.Approved, Investigational
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Ritonavir.Approved
PethidineThe risk or severity of adverse effects can be increased when Ritonavir is combined with Pethidine.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Ritonavir.Withdrawn
PhenforminThe metabolism of Phenformin can be decreased when combined with Ritonavir.Approved, Withdrawn
PhenobarbitalThe serum concentration of Ritonavir can be decreased when it is combined with Phenobarbital.Approved
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be decreased when combined with Ritonavir.Approved
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Ritonavir.Approved
PhenytoinThe serum concentration of Ritonavir can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Ritonavir.Approved
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Ritonavir.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Ritonavir.Approved
PinacidilThe metabolism of Pinacidil can be decreased when combined with Ritonavir.Withdrawn
PindololThe metabolism of Pindolol can be decreased when combined with Ritonavir.Approved
PioglitazoneThe serum concentration of Pioglitazone can be increased when it is combined with Ritonavir.Approved, Investigational
PiperazineThe metabolism of Piperazine can be decreased when combined with Ritonavir.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Ritonavir.Approved
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Ritonavir.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Ritonavir.Approved
Platelet Activating FactorThe serum concentration of Ritonavir can be decreased when it is combined with Platelet Activating Factor.Experimental
PodofiloxThe metabolism of Podofilox can be decreased when combined with Ritonavir.Approved
PomalidomideThe metabolism of Pomalidomide can be decreased when combined with Ritonavir.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Ritonavir.Approved
PosaconazoleThe serum concentration of Ritonavir can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Ritonavir.Approved, Investigational
PranlukastThe serum concentration of Pranlukast can be increased when it is combined with Ritonavir.Approved
PrasteroneThe metabolism of Prasterone can be decreased when combined with Ritonavir.Approved, Nutraceutical
PrasugrelThe serum concentration of the active metabolites of Prasugrel can be reduced when Prasugrel is used in combination with Ritonavir resulting in a loss in efficacy.Approved
PravastatinThe metabolism of Pravastatin can be decreased when combined with Ritonavir.Approved
PrazepamThe metabolism of Prazepam can be decreased when combined with Ritonavir.Approved, Illicit
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Ritonavir.Approved, Vet Approved
PrazosinThe serum concentration of Prazosin can be decreased when it is combined with Ritonavir.Approved
PrednicarbateThe serum concentration of Prednicarbate can be increased when it is combined with Ritonavir.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Ritonavir.Approved, Vet Approved
PrednisoloneThe metabolism of Prednisolone can be decreased when combined with Ritonavir.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Ritonavir.Approved, Vet Approved
PregnenoloneThe serum concentration of Pregnenolone can be increased when it is combined with Ritonavir.Experimental
PrimaquineThe metabolism of Primaquine can be decreased when combined with Ritonavir.Approved
PrimidoneThe serum concentration of Ritonavir can be decreased when it is combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Ritonavir can be increased when it is combined with Probenecid.Approved
ProcainamideRitonavir may increase the QTc-prolonging activities of Procainamide.Approved
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Ritonavir.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Ritonavir.Approved, Vet Approved
ProguanilThe serum concentration of Proguanil can be decreased when it is combined with Ritonavir.Approved
PromazineThe metabolism of Promazine can be decreased when combined with Ritonavir.Approved, Vet Approved
PromethazineThe metabolism of Promethazine can be decreased when combined with Ritonavir.Approved
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Ritonavir.Approved
PropofolThe metabolism of Propofol can be decreased when combined with Ritonavir.Approved, Investigational, Vet Approved
PropranololThe metabolism of Propranolol can be decreased when combined with Ritonavir.Approved, Investigational
ProtriptylineThe metabolism of Protriptyline can be decreased when combined with Ritonavir.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Ritonavir.Approved
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Ritonavir.Approved
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Ritonavir.Approved
QuazepamThe serum concentration of Ritonavir can be increased when it is combined with Quazepam.Approved, Illicit
QuercetinThe serum concentration of Ritonavir can be increased when it is combined with Quercetin.Experimental
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Ritonavir.Approved
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Ritonavir.Approved
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Ritonavir.Approved
QuinineThe serum concentration of Quinine can be decreased when it is combined with Ritonavir.Approved
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Ritonavir.Approved, Investigational
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Ritonavir.Approved, Investigational
RamelteonThe serum concentration of Ramelteon can be increased when it is combined with Ritonavir.Approved, Investigational
RanitidineThe metabolism of Ranitidine can be decreased when combined with Ritonavir.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Ritonavir.Approved, Investigational
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Ritonavir.Approved, Investigational
RegorafenibThe serum concentration of Regorafenib can be increased when it is combined with Ritonavir.Approved
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Ritonavir.Approved, Withdrawn
RepaglinideThe serum concentration of Repaglinide can be increased when it is combined with Ritonavir.Approved, Investigational
repinotanThe metabolism of repinotan can be decreased when combined with Ritonavir.Investigational
ReserpineThe serum concentration of Ritonavir can be decreased when it is combined with Reserpine.Approved
RetapamulinThe serum concentration of Retapamulin can be increased when it is combined with Ritonavir.Approved
RifabutinThe serum concentration of the active metabolites of Rifabutin can be increased when Rifabutin is used in combination with Ritonavir.Approved
RifampicinThe serum concentration of Ritonavir can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Ritonavir can be decreased when it is combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Ritonavir.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Ritonavir.Approved
RimexoloneThe serum concentration of Rimexolone can be increased when it is combined with Ritonavir.Approved
RimonabantThe metabolism of Rimonabant can be decreased when combined with Ritonavir.Approved, Investigational
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Ritonavir.Approved
RisperidoneThe metabolism of Risperidone can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe metabolism of Rivaroxaban can be decreased when combined with Ritonavir.Approved
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Ritonavir.Investigational, Withdrawn
RolapitantThe metabolism of Rolapitant can be decreased when combined with Ritonavir.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Ritonavir.Approved, Investigational
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Ritonavir.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Ritonavir.Approved
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Ritonavir.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Ritonavir.Approved
RotigotineThe metabolism of Rotigotine can be decreased when combined with Ritonavir.Approved
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Ritonavir.Approved, Withdrawn
RuxolitinibThe serum concentration of Ruxolitinib can be increased when it is combined with Ritonavir.Approved
Salicylic acidThe serum concentration of Salicylic acid can be decreased when it is combined with Ritonavir.Approved, Vet Approved
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Ritonavir.Approved
SaquinavirThe metabolism of Saquinavir can be decreased when combined with Ritonavir.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Ritonavir.Approved
ScopolamineThe serum concentration of Ritonavir can be increased when it is combined with Scopolamine.Approved
SecobarbitalThe serum concentration of Ritonavir can be decreased when it is combined with Secobarbital.Approved, Vet Approved
SelegilineThe metabolism of Selegiline can be decreased when combined with Ritonavir.Approved, Investigational, Vet Approved
SelexipagThe metabolism of Selexipag can be decreased when combined with Ritonavir.Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Ritonavir.Approved, Investigational
SertindoleThe metabolism of Sertindole can be decreased when combined with Ritonavir.Approved, Withdrawn
SertralineThe metabolism of Sertraline can be decreased when combined with Ritonavir.Approved
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Ritonavir.Approved, Vet Approved
SibutramineThe metabolism of Sibutramine can be decreased when combined with Ritonavir.Approved, Illicit, Investigational, Withdrawn
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Ritonavir.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Ritonavir.Approved
SiltuximabThe serum concentration of Ritonavir can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Ritonavir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Ritonavir.Approved
SirolimusThe serum concentration of Sirolimus can be increased when it is combined with Ritonavir.Approved, Investigational
SitagliptinThe metabolism of Sitagliptin can be decreased when combined with Ritonavir.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Ritonavir.Approved
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Ritonavir.Approved
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Ritonavir.Approved, Investigational
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Ritonavir.Approved, Investigational
SotalolRitonavir may increase the QTc-prolonging activities of Sotalol.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Ritonavir.Approved
SparteineThe metabolism of Sparteine can be decreased when combined with Ritonavir.Experimental
SphingosineThe serum concentration of Sphingosine can be decreased when it is combined with Ritonavir.Experimental
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Ritonavir.Approved
SpironolactoneThe serum concentration of Ritonavir can be increased when it is combined with Spironolactone.Approved
St. John's WortThe metabolism of Ritonavir can be increased when combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Ritonavir can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Ritonavir can be increased when it is combined with Stiripentol.Approved
StreptozocinThe serum concentration of Ritonavir can be decreased when it is combined with Streptozocin.Approved
SufentanilThe metabolism of Sufentanil can be decreased when combined with Ritonavir.Approved, Investigational
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Ritonavir.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Ritonavir.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Ritonavir.Approved
SulfisoxazoleRitonavir may increase the QTc-prolonging activities of Sulfisoxazole.Approved, Vet Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Ritonavir.Approved, Investigational
SumatriptanThe serum concentration of Ritonavir can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe metabolism of Sunitinib can be decreased when combined with Ritonavir.Approved, Investigational
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Ritonavir.Approved
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Ritonavir.Approved
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Ritonavir.Approved
TacrineThe serum concentration of Ritonavir can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Ritonavir.Approved, Investigational
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Ritonavir.Approved, Investigational
TadalafilThe serum concentration of Tadalafil can be increased when it is combined with Ritonavir.Approved, Investigational
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Ritonavir resulting in a loss in efficacy.Approved
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Ritonavir.Approved, Investigational
TapentadolThe metabolism of Tapentadol can be decreased when combined with Ritonavir.Approved
TasimelteonThe serum concentration of Tasimelteon can be increased when it is combined with Ritonavir.Approved
TasosartanThe metabolism of Tasosartan can be decreased when combined with Ritonavir.Approved
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Ritonavir.Experimental
Taurocholic AcidThe serum concentration of Taurocholic Acid can be decreased when it is combined with Ritonavir.Experimental
TazaroteneThe metabolism of Tazarotene can be decreased when combined with Ritonavir.Approved, Investigational
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Ritonavir.Approved
TegaserodThe metabolism of Tegaserod can be decreased when combined with Ritonavir.Investigational, Withdrawn
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Ritonavir.Approved
TelavancinRitonavir may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinThe metabolism of Telithromycin can be decreased when combined with Ritonavir.Approved
TelmisartanThe serum concentration of Ritonavir can be increased when it is combined with Telmisartan.Approved, Investigational
TemazepamThe metabolism of Temazepam can be decreased when combined with Ritonavir.Approved
TemsirolimusThe risk or severity of adverse effects can be increased when Ritonavir is combined with Temsirolimus.Approved
TeniposideThe metabolism of Teniposide can be decreased when combined with Ritonavir.Approved
TenofovirThe metabolism of Ritonavir can be decreased when combined with Tenofovir.Approved, Investigational
TerazosinThe serum concentration of Ritonavir can be increased when it is combined with Terazosin.Approved
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Ritonavir.Approved, Investigational, Vet Approved
TerfenadineThe serum concentration of Terfenadine can be increased when it is combined with Ritonavir.Withdrawn
TeriflunomideThe serum concentration of Ritonavir can be decreased when it is combined with Teriflunomide.Approved
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Ritonavir.Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Ritonavir.Approved, Investigational
TetrabenazineThe serum concentration of Tetrabenazine can be increased when it is combined with Ritonavir.Approved
TetracyclineThe metabolism of Tetracycline can be decreased when combined with Ritonavir.Approved, Vet Approved
TheophyllineThe metabolism of Theophylline can be decreased when combined with Ritonavir.Approved
ThiazolidinedioneThe therapeutic efficacy of Thiazolidinedione can be decreased when used in combination with Ritonavir.Investigational
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Ritonavir.Approved
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Ritonavir.Approved
TiagabineThe metabolism of Tiagabine can be decreased when combined with Ritonavir.Approved
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Ritonavir.Approved
TicagrelorThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Ritonavir resulting in a loss in efficacy.Approved
TiclopidineThe metabolism of Ticlopidine can be decreased when combined with Ritonavir.Approved
TimololThe metabolism of Timolol can be decreased when combined with Ritonavir.Approved
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Ritonavir.Approved, Investigational
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Ritonavir.Approved
TipranavirThe serum concentration of Ritonavir can be decreased when it is combined with Tipranavir.Approved, Investigational
TixocortolThe serum concentration of Tixocortol can be increased when it is combined with Ritonavir.Approved
TocilizumabThe serum concentration of Ritonavir can be decreased when it is combined with Tocilizumab.Approved
TofacitinibThe serum concentration of Tofacitinib can be increased when it is combined with Ritonavir.Approved, Investigational
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Ritonavir.Approved
TolbutamideThe metabolism of Tolbutamide can be decreased when combined with Ritonavir.Approved
TolterodineThe serum concentration of Tolterodine can be increased when it is combined with Ritonavir.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Ritonavir.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Ritonavir.Approved, Investigational
TorasemideThe metabolism of Torasemide can be decreased when combined with Ritonavir.Approved
ToremifeneThe risk or severity of adverse effects can be increased when Ritonavir is combined with Toremifene.Approved, Investigational
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Ritonavir.Approved, Investigational
TramadolThe serum concentration of Tramadol can be increased when it is combined with Ritonavir.Approved, Investigational
TranylcypromineThe metabolism of Ritonavir can be decreased when combined with Tranylcypromine.Approved
Trastuzumab emtansineThe serum concentration of the active metabolites of Trastuzumab emtansine can be increased when Trastuzumab emtansine is used in combination with Ritonavir.Approved
TrazodoneThe serum concentration of Trazodone can be increased when it is combined with Ritonavir.Approved, Investigational
TreprostinilThe serum concentration of Treprostinil can be increased when it is combined with Ritonavir.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Ritonavir.Approved, Investigational, Nutraceutical
TriamcinoloneThe metabolism of Triamcinolone can be decreased when combined with Ritonavir.Approved, Vet Approved
TriamcinoloneThe risk or severity of adverse effects can be increased when Ritonavir is combined with Triamcinolone.Approved, Vet Approved
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Ritonavir.Approved
TrifluoperazineThe serum concentration of Ritonavir can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Ritonavir can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Ritonavir.Approved
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Ritonavir.Approved, Vet Approved
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Ritonavir.Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Ritonavir.Withdrawn
TroleandomycinThe metabolism of Troleandomycin can be decreased when combined with Ritonavir.Approved
UdenafilThe metabolism of Udenafil can be decreased when combined with Ritonavir.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Ritonavir.Approved
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Ritonavir.Approved
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Ritonavir.Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Ritonavir.Approved, Investigational
VandetanibThe metabolism of Vandetanib can be decreased when combined with Ritonavir.Approved
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Ritonavir.Investigational
VardenafilThe serum concentration of Vardenafil can be increased when it is combined with Ritonavir.Approved
VecuroniumThe serum concentration of Vecuronium can be decreased when it is combined with Ritonavir.Approved
VemurafenibThe serum concentration of Vemurafenib can be increased when it is combined with Ritonavir.Approved
VenetoclaxThe metabolism of Venetoclax can be decreased when combined with Ritonavir.Approved
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Ritonavir.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Ritonavir.Approved
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Ritonavir.Investigational
VilanterolThe metabolism of Vilanterol can be decreased when combined with Ritonavir.Approved
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Ritonavir.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Ritonavir.Approved, Investigational
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Ritonavir.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Ritonavir.Approved, Investigational
VindesineThe serum concentration of Vindesine can be increased when it is combined with Ritonavir.Approved
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Ritonavir.Approved, Investigational
VismodegibThe metabolism of Vismodegib can be decreased when combined with Ritonavir.Approved
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Ritonavir.Approved, Investigational
VorapaxarThe serum concentration of Vorapaxar can be increased when it is combined with Ritonavir.Approved
VoriconazoleThe serum concentration of Voriconazole can be decreased when it is combined with Ritonavir.Approved, Investigational
VortioxetineThe serum concentration of Vortioxetine can be increased when it is combined with Ritonavir.Approved
WarfarinThe serum concentration of Warfarin can be decreased when it is combined with Ritonavir.Approved
YohimbineThe metabolism of Yohimbine can be decreased when combined with Ritonavir.Approved, Vet Approved
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Ritonavir.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Ritonavir.Approved
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Ritonavir.Approved, Illicit, Investigational
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Ritonavir.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Ritonavir.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Ritonavir can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Ziprasidone can be decreased when combined with Ritonavir.Approved
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Ritonavir.Approved
ZomepiracThe metabolism of Zomepirac can be decreased when combined with Ritonavir.Withdrawn
ZonisamideThe metabolism of Zonisamide can be decreased when combined with Ritonavir.Approved, Investigational
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Ritonavir.Approved
ZuclopenthixolThe serum concentration of Zuclopenthixol can be increased when it is combined with Ritonavir.Approved, Investigational
Food Interactions
  • Avoid St.John's Wort.
  • Take with food.
References
Synthesis Reference

DrugSyn.org

US5484801
General ReferencesNot Available
External Links
ATC CodesJ05AR10J05AX67J05AE03J05AX66
AHFS Codes
  • 08:18.08.08
PDB Entries
FDA labelDownload (350 KB)
MSDSDownload (57.4 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.7195
Blood Brain Barrier-0.9717
Caco-2 permeable-0.8957
P-glycoprotein substrateSubstrate0.8307
P-glycoprotein inhibitor IInhibitor0.8317
P-glycoprotein inhibitor IINon-inhibitor0.8753
Renal organic cation transporterNon-inhibitor0.9009
CYP450 2C9 substrateNon-substrate0.694
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.5973
CYP450 1A2 substrateNon-inhibitor0.67
CYP450 2C9 inhibitorNon-inhibitor0.6229
CYP450 2D6 inhibitorNon-inhibitor0.8424
CYP450 2C19 inhibitorInhibitor0.5399
CYP450 3A4 inhibitorInhibitor0.5843
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5946
Ames testNon AMES toxic0.7378
CarcinogenicityNon-carcinogens0.8664
BiodegradationNot ready biodegradable0.9633
Rat acute toxicity2.6154 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9774
hERG inhibition (predictor II)Inhibitor0.8457
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Abbott laboratories pharmaceutical products div
  • Abbott laboratories
Packagers
Dosage forms
FormRouteStrength
Kit; tabletOral
CapsuleOral
SolutionOral
TabletOral
Tablet, film coatedOral
CapsuleOral100 mg
CapsuleOral100 mg/1
SolutionOral80 mg
SolutionOral80 mg/mL
TabletOral100 mg
Tablet, film coatedOral100 mg/1
Kit
Prices
Unit descriptionCostUnit
Norvir 100 mg softgel cap10.29USD softgel capsule
Norvir 100 mg tablet10.29USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2135890 No1996-08-272013-12-16Canada
CA2178632 No2006-04-112015-01-03Canada
US5541206 No1993-07-302013-07-30Us
US5914332 Yes1996-06-132016-06-13Us
US6037157 Yes1996-12-262016-12-26Us
US6232333 Yes1998-05-072018-05-07Us
US6284767 Yes1996-08-152016-08-15Us
US6458818 Yes1998-05-072018-05-07Us
US6521651 Yes1998-05-072018-05-07Us
US6703403 Yes1996-12-262016-12-26Us
US6911214 Yes2002-05-282022-05-28Us
US7141593 Yes2000-11-222020-11-22Us
US7148359 Yes2000-01-192020-01-19Us
US7364752 Yes2001-05-102021-05-10Us
US7432294 Yes2000-11-222020-11-22Us
US8025899 Yes2008-06-142028-06-14Us
US8188104 No2009-05-172029-05-17Us
US8268349 Yes2005-02-252025-02-25Us
US8309613 Yes2005-06-242025-06-24Us
US8377952 Yes2008-04-222028-04-22Us
US8399015 Yes2005-02-252025-02-25Us
US8420596 Yes2011-10-102031-10-10Us
US8466159 No2012-09-042032-09-04Us
US8470347 Yes2007-03-172027-03-17Us
US8492386 No2012-09-042032-09-04Us
US8501219 No2001-11-282021-11-28Us
US8501238 No2008-09-172028-09-17Us
US8642538 No2009-09-102029-09-10Us
US8680106 No2012-09-042032-09-04Us
US8685984 No2012-09-042032-09-04Us
US8686026 No2011-06-092031-06-09Us
US8691878 Yes2005-02-252025-02-25Us
US8691938 No2012-04-132032-04-13Us
US9006387 No2010-06-102030-06-10Us
US9044480 No2011-04-102031-04-10Us
US9139536 No2008-11-092028-11-09Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityPractically insolubleNot Available
logP3.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00126 mg/mLALOGPS
logP4.24ALOGPS
logP5.22ChemAxon
logS-5.8ALOGPS
pKa (Strongest Acidic)13.68ChemAxon
pKa (Strongest Basic)2.84ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area145.78 Å2ChemAxon
Rotatable Bond Count18ChemAxon
Refractivity194.59 m3·mol-1ChemAxon
Polarizability77.4 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as n-carbamoyl-alpha amino acids and derivatives. These are compounds containing an alpha amino acid (or a derivative thereof) which bears an carbamoyl group at its terminal nitrogen atom.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentN-carbamoyl-alpha amino acids and derivatives
Alternative Parents
Substituents
  • N-carbamoyl-alpha-amino acid or derivatives
  • Alpha-amino acid amide
  • Amphetamine or derivatives
  • 2,4-disubstituted 1,3-thiazole
  • Fatty acyl
  • Benzenoid
  • N-acyl-amine
  • Fatty amide
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Thiazole
  • Azole
  • Urea
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Secondary alcohol
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Monocarboxylic acid or derivatives
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human immunodeficiency virus 1
Pharmacological action
yes
Actions
inhibitor
General Function:
Aspartic-type endopeptidase activity
Specific Function:
Not Available
Gene Name:
pol
Uniprot ID:
Q72874
Molecular Weight:
10778.7 Da
References
  1. Garriga C, Perez-Elias MJ, Delgado R, Ruiz L, Najera R, Pumarola T, Alonso-Socas Mdel M, Garcia-Bujalance S, Menendez-Arias L: Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments. J Med Virol. 2007 Nov;79(11):1617-28. [PubMed:17854027 ]
  2. Das A, Rao DR, Hosur MV: X-ray structure of HIV-1 protease tethered dimer complexed to ritonavir. Protein Pept Lett. 2007;14(6):565-8. [PubMed:17627597 ]
  3. Wittayanarakul K, Hannongbua S, Feig M: Accurate prediction of protonation state as a prerequisite for reliable MM-PB(GB)SA binding free energy calculations of HIV-1 protease inhibitors. J Comput Chem. 2008 Apr 15;29(5):673-85. [PubMed:17849388 ]
  4. Markowitz M, Saag M, Powderly WG, Hurley AM, Hsu A, Valdes JM, Henry D, Sattler F, La Marca A, Leonard JM, et al.: A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med. 1995 Dec 7;333(23):1534-9. [PubMed:7477168 ]
  5. Hoetelmans RM, Meenhorst PL, Mulder JW, Burger DM, Koks CH, Beijnen JH: Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir. Pharm World Sci. 1997 Aug;19(4):159-75. [PubMed:9297727 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitorinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitorinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Tanabe M, Hashimoto M, Ono H: Imidazoline I(1) receptor-mediated reduction of muscle rigidity in the reserpine-treated murine model of Parkinson's disease. Eur J Pharmacol. 2008 Jul 28;589(1-3):102-5. doi: 10.1016/j.ejphar.2008.06.013. Epub 2008 Jun 7. [PubMed:18602099 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitorinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Walsky RL, Gaman EA, Obach RS: Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78. [PubMed:15601807 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Perloff MD, Von Moltke LL, Marchand JE, Greenblatt DJ: Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line. J Pharm Sci. 2001 Nov;90(11):1829-37. [PubMed:11745741 ]
  2. Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, Kim RB: Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos. 2000 Jun;28(6):655-60. [PubMed:10820137 ]
  3. Kumar S, Kwei GY, Poon GK, Iliff SA, Wang Y, Chen Q, Franklin RB, Didolkar V, Wang RW, Yamazaki M, Chiu SH, Lin JH, Pearson PG, Baillie TA: Pharmacokinetics and interactions of a novel antagonist of chemokine receptor 5 (CCR5) with ritonavir in rats and monkeys: role of CYP3A and P-glycoprotein. J Pharmacol Exp Ther. 2003 Mar;304(3):1161-71. [PubMed:12604693 ]
  4. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. [PubMed:12699389 ]
  5. Yamazaki M, Neway WE, Ohe T, Chen I, Rowe JF, Hochman JH, Chiba M, Lin JH: In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results. J Pharmacol Exp Ther. 2001 Mar;296(3):723-35. [PubMed:11181899 ]
  6. Huisman MT, Smit JW, Wiltshire HR, Hoetelmans RM, Beijnen JH, Schinkel AH: P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. Mol Pharmacol. 2001 Apr;59(4):806-13. [PubMed:11259625 ]
  7. Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24. [PubMed:12948019 ]
  8. Adachi Y, Suzuki H, Sugiyama Y: Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8. [PubMed:11785684 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitorinducer
General Function:
Transporter activity
Specific Function:
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotrexate, antiviral drugs and other xenobiotics. Confers resistance to anticancer drugs. Hydrolyzes ATP with low efficiency.
Gene Name:
ABCC1
Uniprot ID:
P33527
Molecular Weight:
171589.5 Da
References
  1. Perloff MD, Von Moltke LL, Marchand JE, Greenblatt DJ: Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line. J Pharm Sci. 2001 Nov;90(11):1829-37. [PubMed:11745741 ]
  2. Olson DP, Scadden DT, D'Aquila RT, De Pasquale MP: The protease inhibitor ritonavir inhibits the functional activity of the multidrug resistance related-protein 1 (MRP-1). AIDS. 2002 Sep 6;16(13):1743-7. [PubMed:12218384 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
References
  1. Dussault I, Lin M, Hollister K, Wang EH, Synold TW, Forman BM: Peptide mimetic HIV protease inhibitors are ligands for the orphan receptor SXR. J Biol Chem. 2001 Sep 7;276(36):33309-12. Epub 2001 Jul 20. [PubMed:11466304 ]
  2. Huisman MT, Smit JW, Crommentuyn KM, Zelcer N, Wiltshire HR, Beijnen JH, Schinkel AH: Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. AIDS. 2002 Nov 22;16(17):2295-301. [PubMed:12441801 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibited by the grapefruit juice component naringin.
Gene Name:
SLCO1A2
Uniprot ID:
P46721
Molecular Weight:
74144.105 Da
References
  1. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB: OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos. 1999 Aug;27(8):866-71. [PubMed:10421612 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Gupta A, Zhang Y, Unadkat JD, Mao Q: HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther. 2004 Jul;310(1):334-41. Epub 2004 Mar 8. [PubMed:15007102 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostaglandin E2, thromboxane B2, leukotriene C3, leukotriene E4, thyroxine and triiodothyronine. Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B1
Uniprot ID:
Q9Y6L6
Molecular Weight:
76447.99 Da
References
  1. Tirona RG, Leake BF, Wolkoff AW, Kim RB: Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther. 2003 Jan;304(1):223-8. [PubMed:12490595 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 04, 2016 04:00